3D Global Biotech Inc.
3D Global Biotech Inc. develops medical materials for human body reconstruction in China. It uses cell culture systems, 3D printing technology, and bio-inks hydrogel as the basis to develop and produce customized autologous cell-based medical products. The company develops human tissue and organ reconstruction platforms; develops customized and personalized medical equipment; and conducts profess… Read more
3D Global Biotech Inc. (6808) - Total Liabilities
Latest total liabilities as of June 2025: NT$152.66 Million TWD
Based on the latest financial reports, 3D Global Biotech Inc. (6808) has total liabilities worth NT$152.66 Million TWD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
3D Global Biotech Inc. - Total Liabilities Trend (2019–2024)
This chart illustrates how 3D Global Biotech Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
3D Global Biotech Inc. Competitors by Total Liabilities
The table below lists competitors of 3D Global Biotech Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
UFLEX Limited
NSE:UFLEX
|
India | ₹130.52 Billion |
|
Bank of San Francisco
OTCQX:BSFO
|
USA | $593.39 Million |
|
Orthex Oyj
HE:ORTHEX
|
Finland | €47.28 Million |
|
Centro de Imagem Diagnósticos S.A
SA:AALR3
|
Brazil | R$1.93 Billion |
|
Panacea Biotec Limited
NSE:PANACEABIO
|
India | ₹4.32 Billion |
|
Udaipur Cement Works Limited
NSE:UDAICEMENT
|
India | ₹18.94 Billion |
|
Panda Financial Holding Corp Ltd
SHG:600599
|
China | CN¥184.45 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down 3D Global Biotech Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 11.34 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.17 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how 3D Global Biotech Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for 3D Global Biotech Inc. (2019–2024)
The table below shows the annual total liabilities of 3D Global Biotech Inc. from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$132.88 Million | +333.09% |
| 2023-12-31 | NT$30.68 Million | +0.08% |
| 2022-12-31 | NT$30.66 Million | -11.92% |
| 2021-12-31 | NT$34.81 Million | +3.12% |
| 2020-12-31 | NT$33.75 Million | +429.19% |
| 2019-12-31 | NT$6.38 Million | -- |